RxDoctor Payments Data

Vince Nguyen, MD

Interventional Cardiology · Houston, TXNPI 1952506511

Payments from drug & device makers

$9,396in general payments, 2019–2025

Across 276 payments — averaging $34.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$1K
  • Novartis$703
  • Merck$442
  • Abbott$441
  • Boehringer Ingelheim$437
  • plus $4K from 33 others

What the payments were for

  • Travel & lodging$7928%
  • Food & beverage$8,57891%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,396 in reported general payments places this provider in the 45th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$508,941
Medicare patients
858
Services billed
4,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban397$463,293
XareltoRivaroxaban148$180,436
EntrestoSacubitril/Valsartan95$116,599
FarxigaDapagliflozin Propanediol33$30,341
JardianceEmpagliflozin16$17,027
BrilintaTicagrelor17$10,764
Metoprolol Succinate478$8,041
Ranolazine ErRanolazine58$5,832
Losartan Potassium503$4,766
Rosuvastatin Calcium339$4,462
Atorvastatin Calcium485$4,413
Dabigatran EtexilateDabigatran Etexilate Mesylate14$3,688
ClopidogrelClopidogrel Bisulfate312$3,066
Lisinopril199$2,602
Amiodarone Hcl126$2,572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$246$463,293397 claims
Johnson & JohnsonXarelto$436$180,436148 claims
NovartisEntresto$703$116,59995 claims
AstraZenecaFarxiga, Brilinta$336$41,10450 claims
Boehringer IngelheimJardiance$437$17,02716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →